Table 1.
Clinical characteristics of genotyped patients in the TARGET study.
| All TARGET Patients (n=903) | Genotyped TARGET Patients (n=295) | |||
|---|---|---|---|---|
| Sorafenib (n=451) | Placebo (n=452) | Sorafenib (n=155) | Placebo (n=140) | |
| Male gender - no. (%) | 315 (70) | 340 (75) | 114 (74) | 108 (77) |
| Median age - year (range) | 58 (19–86) | 59 (29–84) | 59 (19–80) | 58 (31–82) |
| ECOG performance status - no. (%) | ||||
| 0 | 219 (49) | 210 (46) | 83 (54) | 81 (58) |
| 1 | 223 (49) | 236 (52) | 72 (46) | 58 (42) |
| 2 | 7 (2) | 4 (1) | 0 | 0 |
| Missing | 2 (<1) | 2 (<1) | 0 | 1 (<1) |
| Number of metastatic sites - no. (%) | ||||
| 1 | 62 (14) | 63 (14) | 26 (17) | 26 (19) |
| 2 | 131 (29) | 129 (29) | 42 (27) | 40 (29) |
| >2 | 256 (57) | 258 (57) | 87 (56) | 74 (53) |
| Missing | 2 (<1) | 2 (<1) | 0 | 0 |
| Lung or liver metastatic sites - no. (%) | 377 (84) | 382 (85) | 133 (86) | 120 (86) |
| Previous cytokine use - no. (%) | 374 (83) | 368 (81) | 141 (91) | 122 (88) |
| Median duration of disease - year (range) | 2 (<1–19) | 2 (<1–20) | 1.7 (<1–19.5) | 1.5 (<1–16) |
| MSKCC prognostic risk - no. (%) | ||||
| Low | 233 (52) | 228 (50) | 73 (47) | 68 (49) |
| Intermediate | 218 (48) | 223 (49) | 82 (53) | 72 (51) |
| Missing | 0 | 1 (<1) | 0 | 0 |
Abbreviations: ECOG, Eastern Cooperative Oncology Group; MSKCC, Memorial Sloan Kettering Cancer Center.